Shares of Arcus Biosciences (RCUS) fell on Thursday after Morgan Stanley downgraded the cancer drug developer to Equal Weight from Overweight, citing a balanced risk-reward setup following the stock's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback